Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 188

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis

Open access
Jabbari, A., Sansaricq, F., Cerise, J., Chen, J.C., Bitterman, A., Ulerio, G., Borbon, J., Clynes, R., Christiano, A.M., Mackay-Wiggan, J. · 2018 · Journal of Investigative Dermatology

Abstract

Alopecia areata (AA) is a common autoimmune disease, with a lifetime risk of ~2%. In AA, the immune systems targets the hair follicle, resulting in clinical hair loss. AA prognosis is unpredictable, and currently there is no definitive treatment. Our previous whole genome expression studies identified active immune circuits in AA lesions, including common γ-chain cytokine and IFN pathways. Since these pathways are mediated through JAK kinases, we prioritized clinical exploration of small molecule JAK inhibitors. In preclinical trials in mice, tofacitinib successfully prevented AA development and reversed established disease. In our tofacitinib trial in 12 patients with moderate to severe AA, 11 patients completed a full course of treatment with minimal adverse events. Following limited response to the initial dose (5mg BID), the dose was escalated (10mg BID) for nonresponding subjects. Eight of 12 patients demonstrated ≥50% hair regrowth while 3 patients demonstrated <50% hair regrowth as measured by SALT score. One patient demonstrated no regrowth. Gene expression profiles and Alopecia Areata Disease Activity Index (ALADIN) scores correlated with clinical response. Our open label studies of ruxolitinib and tofacitinib have shown dramatic clinical responses in moderate-to-severe AA, providing strong rationale for larger clinical trials using JAK inhibitors in AA.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jid.2018.01.032

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 188

Metadata

Authors
Jabbari, A., Sansaricq, F., Cerise, J., Chen, J. C., Bitterman, A., Ulerio, G., Borbon, J., Clynes, R., Christiano, A. M., & Mackay-Wiggan, J.
Venue
Journal of Investigative Dermatology
Publisher
Elsevier BV
Published
2018-07
Volume
138
Issue
7
Pages
1539-1545
ISSN
0022-202X (ISSN-L)
OpenAlex
W2785664987
Cited by
188
References
2
FWCI
23.77
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.